|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STRN4 |
Gene summary for STRN4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STRN4 | Gene ID | 29888 |
| Gene name | striatin 4 | |
| Gene Alias | PPP2R6C | |
| Cytomap | 19q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q59GV6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29888 | STRN4 | C43 | Human | Oral cavity | OSCC | 2.32e-16 | 3.46e-01 | 0.1704 |
| 29888 | STRN4 | C46 | Human | Oral cavity | OSCC | 4.68e-11 | 3.00e-01 | 0.1673 |
| 29888 | STRN4 | C51 | Human | Oral cavity | OSCC | 1.54e-16 | 5.45e-01 | 0.2674 |
| 29888 | STRN4 | C57 | Human | Oral cavity | OSCC | 2.03e-10 | 3.44e-01 | 0.1679 |
| 29888 | STRN4 | C08 | Human | Oral cavity | OSCC | 6.37e-20 | 4.23e-01 | 0.1919 |
| 29888 | STRN4 | LN22 | Human | Oral cavity | OSCC | 7.61e-05 | 7.54e-01 | 0.1733 |
| 29888 | STRN4 | LN46 | Human | Oral cavity | OSCC | 7.57e-12 | 4.46e-01 | 0.1666 |
| 29888 | STRN4 | SYSMH1 | Human | Oral cavity | OSCC | 1.87e-09 | 2.43e-01 | 0.1127 |
| 29888 | STRN4 | SYSMH2 | Human | Oral cavity | OSCC | 6.17e-11 | 3.61e-01 | 0.2326 |
| 29888 | STRN4 | SYSMH3 | Human | Oral cavity | OSCC | 1.04e-18 | 4.06e-01 | 0.2442 |
| 29888 | STRN4 | SYSMH5 | Human | Oral cavity | OSCC | 1.18e-10 | 1.67e-01 | 0.0647 |
| 29888 | STRN4 | SYSMH6 | Human | Oral cavity | OSCC | 3.41e-09 | 1.17e-01 | 0.1275 |
| 29888 | STRN4 | male-WTA | Human | Thyroid | PTC | 4.06e-25 | 3.19e-01 | 0.1037 |
| 29888 | STRN4 | PTC04 | Human | Thyroid | PTC | 4.40e-05 | 1.42e-01 | 0.1927 |
| 29888 | STRN4 | PTC05 | Human | Thyroid | PTC | 1.58e-13 | 3.69e-01 | 0.2065 |
| 29888 | STRN4 | PTC06 | Human | Thyroid | PTC | 1.32e-12 | 1.90e-01 | 0.2057 |
| 29888 | STRN4 | PTC07 | Human | Thyroid | PTC | 2.05e-13 | 2.14e-01 | 0.2044 |
| 29888 | STRN4 | ATC12 | Human | Thyroid | ATC | 6.18e-04 | 1.36e-01 | 0.34 |
| 29888 | STRN4 | ATC13 | Human | Thyroid | ATC | 6.29e-18 | 3.62e-01 | 0.34 |
| 29888 | STRN4 | ATC2 | Human | Thyroid | ATC | 1.01e-04 | 7.67e-01 | 0.34 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STRN4 | SNV | Missense_Mutation | novel | c.2263C>A | p.Leu755Met | p.L755M | Q9NRL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| STRN4 | SNV | Missense_Mutation | rs769814736 | c.644C>T | p.Pro215Leu | p.P215L | Q9NRL3 | protein_coding | tolerated(0.08) | benign(0.138) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| STRN4 | SNV | Missense_Mutation | rs779485652 | c.946N>G | p.Ile316Val | p.I316V | Q9NRL3 | protein_coding | tolerated(0.05) | benign(0.138) | TCGA-E9-A3X8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphane | CR |
| STRN4 | deletion | Frame_Shift_Del | novel | c.847delN | p.Asp283ThrfsTer10 | p.D283Tfs*10 | Q9NRL3 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| STRN4 | SNV | Missense_Mutation | novel | c.1483C>T | p.Arg495Trp | p.R495W | Q9NRL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STRN4 | SNV | Missense_Mutation | c.2042N>G | p.Ser681Cys | p.S681C | Q9NRL3 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| STRN4 | SNV | Missense_Mutation | novel | c.354N>G | p.Ile118Met | p.I118M | Q9NRL3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| STRN4 | SNV | Missense_Mutation | c.1885N>A | p.Val629Ile | p.V629I | Q9NRL3 | protein_coding | deleterious(0) | benign(0.003) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| STRN4 | SNV | Missense_Mutation | c.773N>A | p.Gly258Asp | p.G258D | Q9NRL3 | protein_coding | tolerated(0.22) | benign(0.287) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| STRN4 | SNV | Missense_Mutation | rs560915215 | c.2006N>A | p.Arg669His | p.R669H | Q9NRL3 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |